The global HPV vaccine market is expected to observe a robust growth rate of more than 7% during the forecast period. The HPV vaccine is the first vaccine developed specifically targeting the prevention of cervical cancer. Over 200 million doses have been administrated globally. HPV vaccines are used to cure most cervical cancers associated with human papillomavirus (HPV) a sexually transmitted infection. Extensive immunization with the HPV vaccine could reduce the impact of cervical cancer and other cancers caused by HPV globally.
According to the Centre for Disease Control (CDC), the HPV vaccine should be given to children of ages 11 and 12 and can be given as early as 9. The growing prevalence of HPV-associated diseases, initiatives taken by global health organizations like “GAVI”, and the rising number of HPV awareness programs are some of the key factors responsible to fuel the demand for HPV vaccines across the globe. Moreover, high-income countries (HICs) will make up most of this growth, HICs represent approximately 80% of the HPV vaccine market value. However, limited product offerings in various countries are anticipated to act as a barrier to the growth of the global HPV vaccine market.
The 9-Valent Vaccine (Gardasil 9) is dominating the global market
The 9-Valent Vaccine (Gardasil 9) segment is expected to dominate the global HPV vaccine market followed by Quadrivalent Vaccine (Gardasil). Since 2016, only 9-Valent Vaccines is distributing in the US. The reason behind the significant demand for the 9-valent vaccine is this vaccine protects against nine HPV types (6, 11, 16, 18, 31, 33, 45, 52, and 58) and is safe and also reduces the further incidence of HPV infections as well as HPV related cancer.
Herd immunity can also be used to protect those who have not received a vaccination. The majority of cervical malignancies can be avoided with an efficient immunization program. Studies reveal that the original quadrivalent HPV vaccine and the 9-valent HPV vaccine are both cost-effective for female patients. Consequently, Bivalent Vaccine (Cervarix) segment is expected to hold a nominal share in the global HPV vaccine market.
Sub-Saharan Africa is a high-potential market for manufacturers across the globe
North America is expected to hold a prominent share of the global HPV vaccine market owing to the rapid adoption of the HPV vaccine across the region. Even in countries like US and Canada where the population has access to ideal sanitation and hygienic conditions cervical cancer is controlled through HPV vaccination. The Asia Pacific is expected to gain significant growth during the forecast period due to the growing incidence of HPV diseases.
Countries like India, and China recorded a sudden increase in the number of cervical cancer cases which directly led to the rising demand for the HPV vaccine in the region. Australia was the first country to introduce the HPV vaccine. In India first HPV vaccine is developed in 2022.
Moreover, there is a potential market for manufacturers in low-income countries. Sub-Saharan Africa has made limited progress in the implementation of HPV vaccines owing to weaken social mobilization over time, inadequate reminder and tracking systems, and vaccine hesitancy. Additionally, public demand for the HPV vaccine may be influenced by the level of knowledge, awareness, and attitude of various stakeholders involved in the HPV vaccination program. According to WHO, In Europe, more than 66,000 women are diagnosed with cervical cancer and more than 30,000 of them die annually from cervical.
In the UK, researchers found that the HPV immunization program has almost eliminated cervical cancer in women born after 1 September 1995 and who were vaccinated at age 12−13. Incidence among these women of late-stage grade 3 CIN that could later develop into cancer has also been significantly reduced.
Explore related report: Global mRNA Technology Market
Market Structure and Competitive Landscape
Some of the prominent players operating in the global HPV vaccine market include Merck & Co., GlaxoSmithKline plc, Serum Institute of India Pvt. Ltd., Johnson & Johnson, AstraZeneca, Walvax Biotechnologies, Innovio Pharmaceuticals, Chengdu Institute of Biological Products Co., Ltd., Sanofi, and Shanghai Bowei among others. Among these, Merck & Co. and GlaxoSmithKline plc are the main makers of the HPV vaccine. These companies use all organic and inorganic growth strategies such as expansion and product launches to increase their offering and their reach across the globe.
- In September 2022, India’s indigenously developed cervical cancer vaccine (qHPV Vaccine) with the partnership between the Serum Institute of India (SII), the Department of Biotechnology (DBT), and the Biotechnology Industry Research Assistance Council (BIRAC).
- In April 2022, Merck & Co. announced to expand its vaccine manufacturing in Virginia to 120,000 square ft. to increase the capacity and supply of HPV vaccine.
Key Market Segmentation
RationalStat has segmented the global HPV vaccine market on the basis of type, disease indication, distribution channel, and region.
- By Type
- 9-Valent Vaccine (Gardasil 9)
- Quadrivalent Vaccine (Gardasil)
- Bivalent Vaccine (Cervarix)
- By Disease Indication
- Cervical Cancer
- Genital Warts
- Oropharyngeal Cancer
- Vulvar Cancer
- Penile Cancer
- Vaginal Cancer
- Anal Cancer
- Others (Head Cancer, Neck Cancer, etc.)
- By Distribution Channel
- Doctor Offices / Hospitals
- School-Based Health Centers
- Government Suppliers
- Retail Pharmacies
- Online Pharmacies
- By Region
- North America
- Latin America
- Rest of Latin America
- Western Europe
- Rest of Western Europe
- Eastern Europe
- Rest of Eastern Europe
- Asia Pacific
- South Korea
- ASEAN (Indonesia, Vietnam, Malaysia, etc.)
- Rest of Asia Pacific
- Middle East & Africa
- South Africa
- Rest of the Middle East & Africa
- North America
RationalStat has developed a state-of-the-art research methodology to crunch numbers and provide the best possible real-time insights to clients. We combine a varied range of industry experience, data analytics, and experts’ viewpoint to create a research methodology for market sizing and forecasting.
RationalStat combines a mix of secondary sources as well as primary research to assess the HPV vaccine market size and develop a forecast. Key steps involved in accurately deriving the market numbers are:
- Defining the problem by understanding the type of market and data required by the client.
- Data gathering and collection through relevant paid databases, publicly available sources, company reports, annual reports, surveys, and interviews.
- Formulating a hypothesis to create market numbers, forecasts, influencing factors, and their relevance.
- Evaluating and analyzing the data by referring to data sources utilized and leveraged.
- Validating, interpreting, and finalizing the data by combining the details gathered from primary and secondary sources with the help of experienced analysts.
- Annual reports, company filings, investor presentations, product catalogs, and company documents
- Industry and market-related documents available in the public domain
- Paid database including Bloomberg, Factiva, S&P Capital IQ, FactSet, Refinitiv Eikon, ICIS, EUWID, and Thomson Reuters, among others
- Whitepapers, research papers, and industry blogs.
Why Buy this Report?
The report is intended for global HPV vaccine manufacturers, vaccine companies and providers, health agencies, healthcare providers, hospitals, government organizations, educational organizations, regulatory agencies, and market research firms, among others. The report provides an in-depth analysis of market size, consumption patterns, ongoing market trends and challenges, and future market opportunities. The report will serve as a source for a 360-degree analysis of the market thoroughly delivering insights to clients to find the right answers to their business questions.
Frequently Asked Questions (FAQs)
The Global HPV Vaccine Market is expected to grow at a CAGR of over 7% during the forecast period 2022-2028.
North America is dominating the Global HPV Vaccine Market in 2021.
The Global HPV Vaccine Market is expected to reach US$ 12 billion in 2028.
Initiatives taken by Global Health Organizations for the HPV vaccine are the key drivers of the global HPV Vaccine Market.
Major companies operating in the global HPV vaccine market include Merck & Co., GlaxoSmithKline plc, Serum Institute of India Pvt. Ltd., etc.